Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

@article{Coleman2007SkeletalEO,
  title={Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.},
  author={Robert Coleman and Linda M. Banks and Samia I. Girgis and Lucy Suzanne Kilburn and Eduard Vrdoljak and John L Fox and Simon J. Cawthorn and Ashraf Patel and Claire F Snowdon and Emma Hall and Judith Margaret Bliss and R C Coombes},
  journal={The Lancet. Oncology},
  year={2007},
  volume={8 2},
  pages={119-27}
}
BACKGROUND Tamoxifen preserves bone in postmenopausal women, but non-steroidal aromatase inhibitors accelerate bone loss and increase fracture risk. We aimed to study the effect on bone health in a subgroup of women included in the Intergroup Exemestane Study (IES), a large randomised trial that compared the switch to the steroidal aromatase inhibitor exemestane with continuation of tamoxifen in the adjuvant treatment of postmenopausal breast cancer. METHODS Results were analysed from 206… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 154 extracted citations

Similar Papers

Loading similar papers…